Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$17,500.00

Effects of Cannabinoid Compounds in a Dopamine Deficient Mouse Parkinson's Model

FY 2021-22

Summary
Parkinsons disease is a neurological disorder that results in tremor, postural instability, and difficulty coordinating movement, like walking. Dopamine, an important neurotransmitter involved in motor control, is affected in Parkinsons disease. As dopaminergic neurons degenerate, symptoms of Parkinsons emerge. The standard drug treatment for Parkinsons is the use of L-DOPA, the precursor of dopamine. Unfortunately, prolonged use and high doses of L-DOPA are associated with a condition known as L-DOPA Induced Dyskinesia. Treatments that enhance L-DOPA and reduce the dose required for therapeutic effect are highly desired as they can delay the development of L-DOPA Induced Dyskinesia. The endocannabinoid system contains anandamide (AEA) and 2-arachidonoylglycerol (2-AG), which are endogenous ligands that primarily bind to cannabinoid receptors CB1 in the nervous system. Monoacylglycerol lipase (MAGL) is the enzyme which breaks down 2-AG. Preliminary studies from our lab have shown that the inhibition of MAGL can increase motor activity in mice. In this project, we aim to study the effect of endocannabinoid inhibitors (MAGL inhibition) and cannabinoids including tetrahydrocannabinol (THC), cannabidiol (CBD), and allosteric modulators of CB1 receptors, on enhancing the effects of L-DOPA in an acute mouse model of Parkinsons disease. Our Dopamine Transporter Dopamine Deficient mice (DDD) model has been successfully used to demonstrate the beneficial effects of amphetamine like compounds on enhancing L-DOPA activity. Our main hypothesis is that drug treatments that would increase L-DOPA efficacy or duration in our model would be beneficial for therapeutic intervention in Parkinsons and could potentially reduce or delay the development of L-DOPA Induced Dyskinesia.
Program
Master's Award: Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
466621
Name
Zovko Lola E
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Effects of Cannabinoid Compounds in a Dopamine Deficient Mouse Parkinson's Model
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Animal Model; Cannabidiol; Dopamine System; Dyskinesia; Endocannabinoid System; L-Dopa; Locomotion; Parkinson'S Disease
Abstract
Parkinsons disease is a neurological disorder that results in tremor, postural instability, and difficulty coordinating movement, like walking. Dopamine, an important neurotransmitter involved in motor control, is affected in Parkinsons disease. As dopaminergic neurons degenerate, symptoms of Parkinsons emerge. The standard drug treatment for Parkinsons is the use of L-DOPA, the precursor of dopamine. Unfortunately, prolonged use and high doses of L-DOPA are associated with a condition known as L-DOPA Induced Dyskinesia. Treatments that enhance L-DOPA and reduce the dose required for therapeutic effect are highly desired as they can delay the development of L-DOPA Induced Dyskinesia. The endocannabinoid system contains anandamide (AEA) and 2-arachidonoylglycerol (2-AG), which are endogenous ligands that primarily bind to cannabinoid receptors CB1 in the nervous system. Monoacylglycerol lipase (MAGL) is the enzyme which breaks down 2-AG. Preliminary studies from our lab have shown that the inhibition of MAGL can increase motor activity in mice. In this project, we aim to study the effect of endocannabinoid inhibitors (MAGL inhibition) and cannabinoids including tetrahydrocannabinol (THC), cannabidiol (CBD), and allosteric modulators of CB1 receptors, on enhancing the effects of L-DOPA in an acute mouse model of Parkinsons disease. Our Dopamine Transporter Dopamine Deficient mice (DDD) model has been successfully used to demonstrate the beneficial effects of amphetamine like compounds on enhancing L-DOPA activity. Our main hypothesis is that drug treatments that would increase L-DOPA efficacy or duration in our model would be beneficial for therapeutic intervention in Parkinsons and could potentially reduce or delay the development of L-DOPA Induced Dyskinesia.
Competitiondate
202112
Approvedterm2
1 yr 0 mth
Pinamesdelim
Zovko, Lola E
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~